Metropolitan Life Insurance Company (MetLife)’s Bio-Techne TECH Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,339	Closed	-$446K	–	1899
2024 Q1	$446K	Sell	6,339 -97	-2%	-$6.94K	0.02%	494
2023 Q4	$497K	Sell	6,436 -77	-1%	-$5.07K	0.02%	465
2023 Q3	$443K	Sell	6,513 -347	-5%	-$27.4K	0.02%	464
2023 Q2	$560K	Sell	6,860 -174	-2%	-$14K	0.03%	441
2023 Q1	$522K	Sell	7,034 -1,867	-21%	-$144K	0.03%	453
2022 Q4	$738K	Sell	8,901 -111	-1%	-$8.81K	0.03%	430
2022 Q3	$640K	Sell	9,012 -112	-1%	-$9.68K	0.03%	442
2022 Q2	$791K	Sell	9,124 -244	-3%	-$22.9K	0.03%	425
2022 Q1	$1.01M	Sell	9,368 -15,552	-62%	-$1.6M	0.04%	408
2021 Q4	$3.22M	Sell	24,920 -328	-1%	-$40.2K	0.04%	339
2021 Q3	$3.06M	Sell	25,248 -11,656	-32%	-$1.42M	0.04%	339
2021 Q2	$4.15M	Buy	36,904 +4	+0%	+$421	0.06%	264
2021 Q1	$3.52M	Buy	36,900 +1,184	+3%	+$108K	0.05%	305
2020 Q4	$2.84M	Sell	35,716 -824	-2%	-$59.7K	0.04%	356
2020 Q3	$2.26M	Sell	36,540 -1,528	-4%	-$99.4K	0.04%	383
2020 Q2	$2.51M	Sell	38,068 -9,484	-20%	-$568K	0.04%	338
2020 Q1	$2.25M	Sell	47,552 -2,396	-5%	-$120K	0.05%	340
2019 Q4	$2.74M	Buy	49,948 +92	+0.2%	+$4.83K	0.04%	378
2019 Q3	$2.44M	Sell	49,856 -744	-1%	-$37.3K	0.04%	408
2019 Q2	$2.64M	Sell	50,600 -132	-0.3%	-$6.65K	0.04%	383
2019 Q1	$2.52M	Sell	50,732 -244	-0.5%	-$11K	0.05%	368
2018 Q4	$1.84M	Buy	50,976 +100	+0.2%	+$4.18K	0.04%	474
2018 Q3	$2.6M	Sell	50,876 -140	-0.3%	-$6.2K	0.04%	385
2018 Q2	$1.89M	Buy	51,016 +1,052	+2%	+$40.2K	0.03%	543
2018 Q1	$1.89M	Buy	49,964 +324	+0.7%	+$11.4K	0.03%	567
2017 Q4	$1.61M	Sell	49,640 -97,524	-66%	-$3.1M	0.02%	664
2017 Q3	$4.45M	Buy	147,164 +104	+0.1%	+$3.09K	0.03%	648
2017 Q2	$4.32M	Buy	147,060 +2,148	+1%	+$58.7K	0.03%	659
2017 Q1	$3.68M	Sell	144,912 -352	-0.2%	-$9.09K	0.03%	739
2016 Q4	$3.73M	Sell	145,264 -840	-0.6%	-$22.1K	0.03%	723
2016 Q3	$4M	Sell	146,104 -372	-0.3%	-$10.2K	0.03%	665
2016 Q2	$4.13M	Buy	146,476 +8,844	+6%	+$227K	0.03%	620
2016 Q1	$3.25M	Buy	137,632 +3,808	+3%	+$83.9K	0.03%	711
2015 Q4	$3.01M	Buy	133,824 +744	+0.6%	+$17K	0.02%	733
2015 Q3	$3.08M	Sell	133,080 -1,092	-0.8%	-$27.4K	0.02%	728
2015 Q2	$3.3M	Buy	134,172 +344	+0.3%	+$8.59K	0.02%	749
2015 Q1	$3.35M	Buy	133,828 +4,728	+4%	+$112K	0.02%	700
2014 Q4	$2.98M	Buy	129,100 +1,456	+1%	+$33.3K	0.02%	786
2014 Q3	$2.98M	Buy	127,644 +12,848	+11%	+$301K	0.02%	758
2014 Q2	$2.66M	Buy	114,796 +708	+0.6%	+$15.6K	0.02%	863
2014 Q1	$2.44M	Buy	114,088 +2,204	+2%	+$49.6K	0.02%	883
2013 Q4	$2.65M	Buy	111,884 +500	+0.4%	+$10.8K	0.02%	832
2013 Q3	$2.23M	Sell	111,384 -3,204	-3%	-$60.8K	0.02%	873
2013 Q2	$1.98M	Buy	+114,588	New	+$1.9M	0.02%	894

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TECH Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Bio-Techne (TECH) in Q2 2024, closing a stake of 6,339 shares — an estimated $446K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TECH in Q2 2013 and held it in 44 quarters. The position peaked at $4.45M in Q3 2017. 572 funds tracked by Wall St. Rank hold TECH as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Bio-Techne position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,339 Bio-Techne shares in Q2 2024, an estimated $446K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Bio-Techne in Q2 2013 and held it in 44 quarters.
Metropolitan Life Insurance Company (MetLife)'s Bio-Techne position peaked at $4.45M in Q3 2017.
572 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.